Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 15Neoplasms 10Carcinoma, Renal Cell 8Carcinoma, Hepatocellular 8Melanoma 7Carcinoma, Non-Small-Cell Lung 7Endometrial Neoplasms 6Thyroid Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Thyroid Cancer, Papillary 3Stomach Neoplasms 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Adenocarcinoma, Follicular 3Ovarian Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Glioma 2Carcinoma, Transitional Cell 2Carcinoma 2Biliary Tract Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1

Interventions

Paclitaxel 19pembrolizumab 16Carboplatin 12Bevacizumab 8lenvatinib 6rucaparib 5Nivolumab 5Megestrol Acetate 5Radiation 4Indocyanine Green 4Gemcitabine 4Cisplatin 4tisotumab vedotin 3temsirolimus 3Sirolimus 3Sentinel Lymph Node Biopsy 3Magnetic Resonance Spectroscopy 3Doxorubicin 3olaparib 2niraparib 2ixabepilone 2iso-sulfan blue 2irosustat 2epacadostat 2durvalumab 2copanlisib 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Endometrial Neoplasms × lenvatinib × Clear all
NCT03517449 2026-03-19

MK-3475-775

Eisai Inc.

Phase 3 Completed
827 enrolled 34 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Merck Sharp & Dohme LLC

Phase 3 Completed
842 enrolled 25 charts
Gynecologic

Endometrial Neoplasms

NCT04865289 2025-12-02

LEAP-001

Merck Sharp & Dohme LLC

Phase 3 Completed
130 enrolled 24 charts
Gynecologic

Endometrial Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Virginia Commonwealth University

Phase 2 Terminated
4 enrolled 8 charts
Gynecologic

Recurrence, Endometrial Neoplasms

NCT01111461 2023-06-22

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Eisai Inc.

Phase 2 Completed
133 enrolled 16 charts
Gynecologic

Endometrial Neoplasms

NCT03006887 2021-05-20

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1 Completed
6 enrolled 27 charts
GenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡